Anavex Life Sciences Statistics
Share Statistics
Anavex Life Sciences has 85.37M
shares outstanding. The number of shares has increased by 0.5%
in one year.
| Shares Outstanding | 85.37M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0.29% |
| Owned by Institutions (%) | 34.83% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 22,793 |
| FTD / Avg. Volume | 2.27% |
Short Selling Information
The latest short interest is 23.49M, so 27.62% of the outstanding
shares have been sold short.
| Short Interest | 23.49M |
| Short % of Shares Out | 27.62% |
| Short % of Float | 28.48% |
| Short Ratio (days to cover) | 42.03 |
Valuation Ratios
The PE ratio is -11.03 and the forward
PE ratio is 6.2.
Anavex Life Sciences's PEG ratio is
0.83.
| PE Ratio | -11.03 |
| Forward PE | 6.2 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 3.94 |
| P/FCF Ratio | -15.39 |
| PEG Ratio | 0.83 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Anavex Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.86,
with a Debt / Equity ratio of 0.
| Current Ratio | 8.86 |
| Quick Ratio | 8.86 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,023,857.14 |
| Employee Count | 42 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.29M |
| Effective Tax Rate | 5.06% |
Stock Price Statistics
The stock price has increased by 85.11% in the
last 52 weeks. The beta is 0.82, so Anavex Life Sciences's
price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | 85.11% |
| 50-Day Moving Average | 8.92 |
| 200-Day Moving Average | 8 |
| Relative Strength Index (RSI) | 44.14 |
| Average Volume (20 Days) | 1,006,296 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -52.88M |
| Net Income | -43M |
| EBITDA | -45.29M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.52 |
Full Income StatementBalance Sheet
The company has 132.19M in cash and 0 in
debt, giving a net cash position of 132.19M.
| Cash & Cash Equivalents | 132.19M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -336.07M |
| Total Assets | 124.04M |
| Working Capital | 110.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -30.81M
and capital expenditures 0, giving a free cash flow of -30.81M.
| Operating Cash Flow | -30.81M |
| Capital Expenditures | n/a |
| Free Cash Flow | -30.81M |
| FCF Per Share | -0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
